Dipna Pharmachem Ltd vs Medicamen Organics Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 19, 2026

Key Highlights

The Latest Trading Price of Dipna Pharmachem Ltd is ₹ 7.5 as of 15 May 15:30 . The P/E Ratio of Dipna Pharmachem Ltd is 0 as of March 2024 .The P/E Ratio of Medicamen Organics Ltd is 0 as of March 2024 . The Market Cap of Dipna Pharmachem Ltd is ₹ 0 crore as of March 2024 .The Market Cap of Medicamen Organics Ltd is ₹ 0 crore as of March 2024 . The Dividend Payout of Dipna Pharmachem Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Medicamen Organics Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Dipna Pharmachem Ltd

Dipan Pharmachem Limited was incorporated on July 19, 2011.
Subsequently, the Company name was changed to 'Dipna Pharmachem Private Limited' on March 29, 2012.
Later on, it was converted from Private Limited to Public Limited and the name of Company was changed to 'Dipna Pharmachem Limited' vide fresh Certificate of Incorporation issued by Registrar of Companies, Ahmedabad dated May 25, 2022. Dipna Pharmachem Limited is a trader, importer, and exporter in industrial Chemical and Pharmaceutical Raw materials, APIs, solvents, and Formulation since 2011.
Presently, its product portfolio comprises of 61 AIPs and AIPs intermediates such as Cephalosporins, Cardiovasculars, Anti - Bactaria, Quinolones, Veterinary, Anti - Virus, Anti - Inflammatory, Neuropsychiatry, Steroid Hormone, other etc.

About Medicamen Organics Ltd

Medicamen Organics Limited was formerly incorporated on March 15, 1995 as Panchdeep Pharmaceuticals Limited', as Public Limited Company dated March 15, 1995 issued by the Registrar of Companies, Delhi and Haryana.
Subsequently, the name of Company changed to Medicamen Organics Limited' and a fresh Certificate of Incorporation on November 14, 1995 was issued by the Registrar of Companies, Delhi and Haryana at Delhi. Medicamen Organics are engaged in developing, manufacturing and distribution of broad range of pharmaceutical dosage including generic dosage in form of Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry Powders for Government (including both State and Central Governments) and Private Institutions as contract manufacturer / third party manufacturer.
The product portfolio consists of 84 products and comprises of wide range of drugs like, Anti-Bacterial, Anti Diarrheal, Anti-Fungal, Anti-Malarial, Anti Diabetic, Proton Pump Inhibitor, Anti Histamine, Anti-Hypertensive drugs, Anti Lipidemic Drug, Anti Parasitic, Multivitamin, Multimineral and Nonsteroidal anti-inflammatory drug (NSAIDS).

FAQs for the comparison of Dipna Pharmachem Ltd and Medicamen Organics Ltd

Which company has a larger market capitalization, Dipna Pharmachem Ltd or Medicamen Organics Ltd?

Market cap of Dipna Pharmachem Ltd is 19 Cr while Market cap of Medicamen Organics Ltd is 31 Cr

What are the key factors driving the stock performance of Dipna Pharmachem Ltd and Medicamen Organics Ltd?

The stock performance of Dipna Pharmachem Ltd and Medicamen Organics Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dipna Pharmachem Ltd and Medicamen Organics Ltd?

As of May 19, 2026, the Dipna Pharmachem Ltd stock price is INR ₹7.5. On the other hand, Medicamen Organics Ltd stock price is INR ₹27.0.

How do dividend payouts of Dipna Pharmachem Ltd and Medicamen Organics Ltd compare?

To compare the dividend payouts of Dipna Pharmachem Ltd and Medicamen Organics Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.